Cancer vaccine, in combination with other immunotherapy-based approaches such as cytokine therapy, in particular, low dose IL-2 and IFN-α, may stimulate promising outcomes in RCC patients [80, 81]. The gene discussed is IL2; the disease is renal cell carcinoma.